Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity
The APPROACH Extension Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx)
ISIS 304801-CS7, The APPROACH Open Label Extension Study Volanesorsen (ISIS 304801) An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS).
Liver Diseases – NAFLD, NASH, and PBC
Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) are common fatty liver diseases that afflict a relatively large percentage of the U.S. population. Risk factors include Type 2 Diabetes, hypertension, high triglycerides, high LDL cholesterol, being overweight and obesity.
Primary Biliary Cholangitis (PBC) is a chronic liver disease resulting from the progressive destruction of the bile ducts in the liver.
Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of NGM282 in Non-alcoholic Steatohepatitis (NASH)
Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Urosodeoxycholic Acid (UDCA)
ISIS 703802-CS2 NAFLD
A Study of ISIS 703802 in Subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
A Study to Evaluate Seladelpar in Subjects with Non-alcoholic Steatohepatitis (NASH)
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily versus Placebo in Subjects with Non-alcoholic Steatohepatitis
A Study to Evaluate the Safety, Tolerability, and Efficacy of MSDC 0602K in Patients with NASH
Clinical Trial in Adults at High-Risk for Fatty Liver Disease
A cross-sectional study evaluating the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in high-risk undiagnosed adults in South Florida.
Phase 2 Study of MGL-3196 in Patients with Non-Alcoholic Steatohepatitis (NASH).
EMPagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
A phase III randomized, double-blind placebo controlled trial to evaluate efficacy and safety of once daily empagliflozin 10 mg in patients with heart failure with preserved ejection fraction.
EMPagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
A phase III randomized, double-blind study to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF < 40%).
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia (HoFH)
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia
Study of Evinacumab (REGN1500) in Participants with Persistent Hypercholesterolemia
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia (HeFH)
Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
Study in Participants ≥12 years of age with Homozygous Familial Hypercholesterolemia (HoFH)
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
AAV8-mediated low density lipoprotein receptor (LDLR) gene replacement in subjects with homozygous familial hypercholesterolemia (HoFH).
Hyperlipidemia / Hypercholesterolemia
Hyperlipidemia/Hypercholesterolemia (elevated lipids/cholesterol) represent the greatest population attributable risk for cardiovascular disease (CVD).
A Study with Bempedoic Acid plus Ezetimibe Fixed-Dose Combination (FDC) Study in Patients with Type 2
Diabetes and Elevated LDL-C
A Study in Subjects with Type 2 Diabetes Mellitus with Hypercholesterolemia/Mixed Dyslipidemia
Cascade Screening for Awareness and Detection of familial hypercholesterolemia.
LOWER: Lomitapide observational worldwide evaluation registry. This registry is a multicentre, long-term, prospective, observational cohort study designed to evaluate the long term safety and effectiveness of lomitapide.
A 12-week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins (ROYAL-1).
Getting to an improved understanding of LDL-C and dyslipidemia management (GOULD): a registry of high cardiovascular risk patients in the United States.
ODYSSEY DM-Dyslipidemia Study
A randomized, open-label, parallel group study to evaluate the efficacy and safety of alirocumab versus usual care in patients with Type 2 Diabetes and mixed dyslipidemia at high cardiovascular risk with non-HDL- C not adequately controlled with maximally tolerated statin therapy.
Inclisiran for Participants with Atherosclerotic Cardiovascular Disease and Elevated Low-Density Lipoprotein Cholesterol
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in patients with Treated with Maximally Tolerated Statin Therapy
1002-047 CLEAR Wisdom
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk
Triple Therapy in Patients with Elevated LDL-C
Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg
1002-040 CLEAR Harmony
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients with Hyperlipidemia and High CV Risk
Hyperlipoproteinemia(a), or elevated Lp(a), is a common condition in the U.S. Elevated levels of Lp(a) are correlated with heart attack, stroke, and aortic stenosis (narrowing of the aortic valve).
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients with Hyperlipoproteinemia(a) and Cardiovascular Disease
A randomized, double-blind, placebo-controlled, dose-ranging phase 2 study of ISIS 681257 administered subcutaneously to patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Study of ISIS 678354 (AKCEA-APOCIII-LR) in Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Outcomes Study to Assess Statin Residual risk reduction with EpaNova in high CV risk patients with Hypertriglyceridemia
Statin medications are a type of lipid lowering therapy. Some individuals cannot tolerate statin medications because of a variety of side effects.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C.
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant.
Cardiovascular Inflammation Reduction Trial
Bexagliflozin Efficacy and Safety Trial
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.